2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide hydrobromide

• ChemBase编号: 165412
• 分子式: C28H31BrN2O2
• 平均质量: 507.46194
• 单一同位素质量: 506.15689024
• SMILES: C(Cc1cc2c(cc1)OCC2)N1C[C@@H](CC1)C(c1ccccc1)(c1ccccc1)C(=O)N.Br
• Canonical SMILES: NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2.Br
• InChI: InChI=1S/C28H30N2O2.BrH/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26;/h1-12,19,25H,13-18,20H2,(H2,29,31);1H/t25-;/m1./s1
• InChIKey: UQAVIASOPREUIT-VQIWEWKSSA-N

名称和登记号

名称

• IUPAC标准名: 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide hydrobromide
• IUPAC传统名: darifenacin hydrobromide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide hydrobromide
• 别名: Enablex; Emselex; Darifenacin Hydrobromide; (3S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-α-α-diphenyl-3-pyrrolidineacetamide Hydrobromide; Darifenacin hydrobromide; Darifenacin HBr

登记号

• CAS号: 133099-07-7
• PubChem SID: 162259545
• PubChem CID: 444030

理论计算性质

• Acid pKa: 16.212147
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): 1.0715904
• LogD (pH = 7.4): 1.896206
• Log P: 4.540284
• 摩尔折射率: 128.3747 cm^3
• 极化性: 49.758102 Å^3
• 极化表面积: 55.56 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Chloroform; DMSO; Methanol
• 外观: White Solid
• 熔点: 228-230°C

安全信息

• 保存条件: -20°C Freezer

药理学性质

• 作用靶点: AChR
• 生物活性机理: Works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions

产品相关信息

• 成盐信息: HBr
• 应用领域: Used to treat urinary incontinence

详细说明

Toronto Research Chemicals - D193400

Used as a medication to treat urinary incontinence. It works by blocking the M3 muscarinic acetylcholine receptor.

参考文献

• Beaumont, K.C., et al.: Xenobiotica, 28, 63 (1998)
• Chapple, C.R., et al.: Expert Opin. Invest. Drugs, 13, 1493 (1998)
• Haab, F., et al.: Eur. Urol., 45, 420 (1998)
• Liver Physiol. 2010 Jul;299(1):G215-9. Epub 2010 Apr 15.
• 3. Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16.
• 1. Bharucha AE, Ravi K, Zinsmeister AR: Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest
• 2. Bozkurt TE, Sahin-Erdemli I: M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. Epub 2009 Feb 5.